期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 10, 期 15, 页码 2395-2397出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560903176453
关键词
cardiovascular disease; diabetes mellitus; metformin; oral hypoglycaemic agents
Metformin has now been established as the drug of choice for the first-line management of type 2 diabetes mellitus. It reduces insulin resistance, improves glycaemic control, and can be safely combined with other classes of oral hypoglycaemic agents. Equally important, metformin has been shown to have a significant beneficial effect on cardiovascular morbidity. Moreover, this agent acts favourably on blood pressure, lipids, haemostasis and other features of the metabolic syndrome. Metformin also contributes to weight reduction and diabetes prevention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据